Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Pharmacology/Therapy

The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer: A systematic review

Gynecologic Oncology | Apr 30, 2019 Pharmacology/Therapy

Total and out-of-pocket costs of different primary management strategies in ovarian cancer

American Journal of Obstetrics and Gynecology | Apr 30, 2019 Pharmacology/Therapy

Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer

Lung Cancer | Apr 30, 2019 Pharmacology/Therapy

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

The Breast | Apr 30, 2019 Pharmacology/Therapy

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

The Breast | Apr 30, 2019 Pharmacology/Therapy

Phase III trials in ovarian cancer: The evolving landscape of front line therapy

Gynecologic Oncology | Apr 29, 2019 Pharmacology/Therapy

The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)

Gynecologic Oncology | Apr 29, 2019 Pharmacology/Therapy

Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy

The Breast | Apr 29, 2019 Pharmacology/Therapy

Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma

Journal of Clinical Oncology | Apr 28, 2019 Pharmacology/Therapy

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin

Gynecologic Oncology | Apr 28, 2019 Pharmacology/Therapy

« Prev 1 … 214 215 216 217 218 … 375 Next »

The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer: A systematic review

Total and out-of-pocket costs of different primary management strategies in ovarian cancer

Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

Phase III trials in ovarian cancer: The evolving landscape of front line therapy

The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)

Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy

Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin

Article on Tirzepatide: Latest Guidelines, Uses, and Clinical Evidence in Obesity and Diabetes Management

Article: Biomarkers in Interstitial Lung Disease (ILD): What's New?

Article: Dietary Approaches for Managing Inflammatory Conditions

Married people may have better colorectal cancer outcomes, study shows

Mediterranean diet provides symptom relief for patients with ibs in pilot study

The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer: A systematic review

Total and out-of-pocket costs of different primary management strategies in ovarian cancer

Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

Phase III trials in ovarian cancer: The evolving landscape of front line therapy

The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)

Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy

Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin

Article on Tirzepatide: Latest Guidelines, Uses, and Clinical Evidence in Obesity and Diabetes Management

Article: Biomarkers in Interstitial Lung Disease (ILD): What's New?

Article: Dietary Approaches for Managing Inflammatory Conditions

Married people may have better colorectal cancer outcomes, study shows

Mediterranean diet provides symptom relief for patients with ibs in pilot study

Select Specialty

Select Topic